ChromoBlog

Recent Posts

Novel cell cycle modulators identified using the Cell Cycle Chromobody Technology

Posted by Larisa Yurlova on Jun 6, 2016 5:25:06 PM

Cell cycle and cell proliferation are tightly controlled cellular processes, and their deregulation is a hallmark of cancer. To enable non-invasive analysis of cell cycle in living cells, ChromoTek developed a Cell Cycle Chromobody. The Cell Cycle Chromobody (CCC) consists of a binding domain of a heavy-chain antibody highly specific against human proliferating cell nuclear antigen (PCNA), which is genetically fused to a fluorescent protein.

Read More

Topics: Cell Cycle Chromobody, Chromobody, live cell imaging

Chromobody® plasmids: Good things come to those who wait!

Posted by Kourosh Zolghadr on Jun 5, 2014 4:50:00 PM

This time last spring we started marketing our Chromobody® plasmids. Our customers realized the impact of the technology and were immediately beginning to work with the Chromobodies®. Now, one year later the first papers are being published demonstrating the broad applicability of this intracellular fluorescent antibody technology: 

The first is a paper in Molecular Cell by the Lindqvist Lab at the Karolinska Institutet in Stockholm, Sweden. They developed a FRET-based system for accurate quantification of fluorescence from single cells. By visualizing endogenous PCNA at replication foci with the Cell Cycle Chromobody® they nicely show that the mitotic entry network is linked to the completion of S phase. It does not depend on protein accumulation through G2 but is activated by mitotic phosphorylations at the end of S phase. The method they present allows analyzing live-cell as well as extracting temporal information from fixed cells based on endogenous marker proteins. (Akopyan, K.; Silva Cascales, H.; Hukasova, E., et al. Assessing kinetics from fixed cells reveals activation of the mitotic entry network at the S/G2 transition. Molecular cell. 2014, 53, 843-853. http://dx.doi.org/10.1016/j.molcel.2014.01.031

Read More

Topics: Chromobodies, Cell Cycle Chromobody, Chromobody, Chromobody plasmid, Actin Chromobody, Lamin Chromobody, Dnmt1 Chromobody, custom Chromobody, intracellular antibody, PCNA

ChromoTek's Chromobody® Technology for HC drug profiling licensed to Bayer

Posted by Katrin Schmidthals on Mar 18, 2013 11:21:00 AM

ChromoTek GmbH (Munich, Germany) has announced today the signing of a license agreement granting Bayer Pharma AG (Bayer) the right to use ChromoTek's proprietary Cell Cycle Chromobody® Technology for drug profiling by High Content Analysis. Under the terms of the agreement, Bayer will apply Chromobody® technology for real time monitoring of cell cycle progression in drug discovery. Financial terms of the agreement were not disclosed. This agreement follows a collaboration in which ChromoTek provided custom cell line development.

ChromoTek's Chromobody® Technology is a patented, universal live cell imaging technology for high content analysis. Chromobodies are single domain antibodies that have been genetically fused to fluorescent proteins to serve as functional nanoprobes in living cells. The Chromobody® technology allows for the first time to trace endogenous intracellular antigens and to visualize dynamic changes of these targets within living cells. Currently available Chromobodies trace important cellular processes like cell cycle, apoptosis, DNA damage and repair or allow cytoskeletal analysis. The Cell Cycle Chromobody® cell line licensed by Bayer traces the complete cell cycle in real time in live cells in a non-invasive manner while providing full flexibility to multiplex with other procedures.

Dr. Kourosh Zolghadr, Head of R&D at ChromoTek comments: "We are pleased to offer our customers efficient tools for achieving more detailed and physiologically relevant information on the effects of drug candidates on cell cycle progression."

About ChromoTek

ChromoTek products set new benchmarks for cellular research. Established in 2008 as a spin-off from Munich’s Ludwig Maximilian University and located in Martinsried, Germany’s leading biotech cluster, ChromoTek develops and markets Chromobody® based live cell assays for drug screening and target validation. Other products include immunological and bioimaging reagents such as the GFP- Trap® for the rapid pull-down of GFP fusion proteins, GFP and RFP-Booster to amplify fluorescence signals of GFP or RFP fusion proteins. ChromoTek’s newly developed fluorescence based protein protein interaction assay called Fluorescent-2-Hybrid (F2H® assay) is available as a development service. More than 2.800 customers from all over the world trust in ChromoTek products.

Download Press release

Posted by Katrin on Mar 18, 2013

Read More

Topics: Chromobodies, Nano-Traps, Nano-Booster, F2H assay, GFP-Trap, Nano-Trap, high content analysis, HCA, Chromobody cell line, Cell Cycle Chromobody

ChromoBlog

Posted by

Subscribe to Email Updates

Recent Posts

Posts by Topic

see all